

Guidance document
Procedure with prior notification

Identification number: ZL101_00_013
Version: 4.1
Valid from: 01.06.2023

List of contents

1	Terms, definitions, abbreviations	3
1.1	Abbreviations.....	3
2	Introduction	3
3	Objective	3
4	Scope	4
5	Description	4
5.1	Requests for a procedure with prior notification	4
5.1.1	Conditions under which a procedure with prior notification can be carried out	4
5.1.2	Documentation required for the request.....	5
5.1.3	Processing the request.....	5
5.1.4	Combining an application for FTP with a PPN request.....	5
5.2	Planning the submission after approval of the PPN application	6
5.2.1	Stating the submission date.....	6
5.2.2	Presubmission Meeting (optional).....	6
5.3	Authorisation procedure with PPN	7
5.3.1	Submission and documentation.....	7
5.3.2	Evaluation phase and periods.....	7
5.3.3	Product information / labelling phase and packaging materials.....	8
5.3.4	Sample testing.....	8
5.3.5	Failure to respect time limits	8
5.3.6	Fees for applications in the PPN procedure.....	9
5.4	Flow chart.....	10

1 Terms, definitions, abbreviations

1.1 Abbreviations

FTP	Fast-track authorisation procedure
FeeO-Swissmedic	Ordinance on the Fees charged by the Swiss Agency for Therapeutic Products of 14 September 2018 (SR 812.214.5)
AI	Additional Indication
CC	Company correction
CD	Calendar days
eCTD	Electronic submission in CTD format
eDok	Swissmedic application submission format, paper version + electronic version
EMA	European Medicines Agency
FDA	Food and Drug Administration
FC	Formal check
LoQ	List of Questions
NA	New application
NAS	New Active Substance
ODS	Orphan Drug Status
PD	Preliminary Decision
PPN	Procedure with Prior Notification
TPO	Ordinance of 21 September 2018 on Therapeutic Products (Therapeutic Products Ordinance, TPO) (SR 812.212.21)

2 Introduction

This guidance document describes in detail the conditions under which a PPN procedure is carried out, from the initial request, review of the request and preparatory work through to the submission of the PPN application and corresponding criteria.

Swissmedic uses this guidance document first and foremost as a resource for applying the legal provisions in a uniform and equitable manner. For applicants, the document is intended to make clear the specific requirements that must be fulfilled so that corresponding applications can be processed by Swissmedic as quickly and efficiently as possible.

3 Objective

The procedure with prior notification (PPN) allows companies that submit applications for the authorisation of human medicinal products with new active substances (New API) and preparations specified in Art. 12 para. 5 TPLO (human medicinal products with a known active substance that cannot be authorised via the simplified procedure) or for an additional indication (AI) to request Swissmedic to consider whether their application with a previously agreed timeframe can be processed within a timeframe that is 20 per cent shorter. In return, the applicant is willing to pay double the fee (Art. 7 FeeO-Swissmedic).

However, in contrast to the fast-track authorisation procedure (FTP) in accordance with Art. 7 of the Therapeutic Products Ordinance (TPO), the PPN procedure does not confer upon the applicant any

legal entitlement to a shorter procedure. Instead, the PPN procedure represents a special service offered by Swissmedic which, under certain conditions, makes it possible to reserve the resources required to carry out a normal authorisation procedure in advance, and thus to process the application more rapidly.

PPN is not an authorisation procedure with a reduced scope of assessment or reduced requirements with regard to the documentation required.

4 Scope

This guidance document applies to the Swissmedic Authorisation division that deals with applications for human medicinal products.

5 Description

5.1 Requests for a procedure with prior notification

5.1.1 Conditions under which a procedure with prior notification can be carried out

The following conditions must be fulfilled before an authorisation application can be processed within the framework of a PPN:

- The authorisation application must concern the **first authorisation** of a human medicinal product with a new active substance (New API), the first authorisation of a preparation specified in Art. 12 para. 5 TPLO, an **additional indication** (AI) for a human medicinal product that was originally authorised as a New API or as a preparation specified in Art. 12 para. 5 TPLO, an **additional pharmaceutical form** and/or an **additional dosage recommendation**; for these last two application types, however, the applications must be submitted together with the application for the first authorisation of the New API / preparation specified in Art. 12 para. 5 TPLO.
- The clinical and preclinical studies should have been fully completed by the time the application is submitted. Once the application has been received, no further trial data, trial results or other documentation relevant to the evaluation may be submitted. If the indication requires long-term data, this data must be available at the time of submission. Interim analyses must be submitted together with the planned, complete and final study report in accordance with the study protocol, reflecting the status once the primary end point of the study has been reached. Full documentation must also be submitted. The submission must be based on up-to-date data and may not contain any immature or incomplete data. The subsequent submission at a later date of further documentation that is not explicitly requested is not possible within the framework of the ongoing procedure. Any results from foreign assessments available to the applicant, and in particular assessment reports from the EMA or the FDA, must be included with the submission.
- Swissmedic must have the necessary human resources available in order to complete the assessment of the application within the required time and by the date foreseen.

A request for a PPN procedure can be sent to Swissmedic at the earliest six months prior to the expected submission date and must be received at the latest three months prior to the expected date. A request for an additional indication in the PPN procedure cannot be submitted until the preliminary decision (PD) on the human medicinal product with a new API / preparation specified in Art. 12 para. 5 TPLO has been issued.

A PPN procedure is only possible if the authorisation application is submitted in CTD format in electronic form as an eCTD application or as a paper version with CD/DVD (eDok). If it is planned to make the submission in eCTD format, it is strongly recommended that applicants with limited or no

experience with eCTD submit a test sequence in good time (at least three weeks before submitting the application) in order to avoid exceeding the time limits as a result of technical problems.

The authorisation application must then be submitted by the deadline established by Swissmedic (within the calendar week) and fulfil all the formal requirements.

5.1.2 Documentation required for the request

A written request for a PPN procedure must include the documents listed in the *Table of documents to be submitted HMV4* on the Applications+Meetings sheet. The cover letter should also contain the following information:

- Name of active pharmaceutical ingredient
- Name of the medicinal product
- For biosimilars the name of the reference preparation as well
- ATC / IT group
- Pharmaceutical form and, for injectable solutions, information about the primary container or – if relevant – the administration system (pre-filled syringe, autoinjector)
- Indication(s) and dosage recommendation(s)
- List of preclinical and clinical studies, in particular with essential information on the pivotal studies
- Expected submission date for the PPN application (+/- 2 calendar weeks)
- Possible date(s) for a Presubmission Meeting or reasons why such a meeting is not felt to be necessary

5.1.3 Processing the request

Within 30 CD, Swissmedic decides whether it will be possible to conduct the procedure requested under the prevailing circumstances on the date proposed by the company (+/- 2 calendar weeks). The outcome of this investigation is communicated to the applicant in writing. If it is not possible to carry out a PPN procedure on the date proposed by the applicant, Swissmedic considers alternative dates and suggests an alternative in its response. If the two parties are unable to agree on an alternative submission date, the applicant is informed that a PPN procedure cannot be carried out during the proposed timeframe.

5.1.4 Combining an application for FTP with a PPN request

A request for a PPN procedure can be submitted at the same time as an application for a fast-track authorisation procedure (FTP) under the terms of Art. 7 TPO. To this end, all the required information and documentation for the FTP application and the request for a PPN must be submitted concurrently. This avoids the need to submit a request for a PPN procedure at a later stage if the application for a FTP is rejected.

In the event of a negative preliminary decision on fast-track authorisation, Swissmedic requires the applicant to confirm, within 7 days of receipt of the negative preliminary decision, that they are continuing with the requested PPN procedure (with suggested deadlines for submitting the request and, where appropriate, for the Presubmission Meeting). In the event of a rejection of the FTP application with simultaneous request for a PPN, the applicant will be charged for the costs of the FTP application. Furthermore, the information in the *Fast-track authorisation procedure* guidance document applies to the application and to the request for a FTP.

5.2 Planning the submission after approval of the PPN application

5.2.1 Stating the submission date

If the company has been informed that a PPN procedure is possible within the timeframe it has proposed, it must inform Swissmedic in writing of the definitive submission date (+5 CD) for the PPN application (definitive prior notification) at the latest one month before this date. In this notification, the applicant should also state the submission format: eCTD or eDok. If, on this definitive submission date, particular developments in the human resources situation at Swissmedic make the performance of a PPN procedure unrealistic, the Agency will inform the applicant immediately and propose an alternative submission date for the PPN application or the submission of the authorisation application in the standard procedure.

5.2.2 Presubmission Meeting (optional)

If necessary, a Presubmission Meeting takes place one or two months before the PPN application is submitted. The aim of the meeting is to establish whether all the documentation required to process the application is available. The following formal aspects of the authorisation application to be submitted, in particular, will be considered:

- Index of scientific and administrative documentation
- Any open questions about the documentation
- Manufacturers involved
- Date of the eCTD test submission (if an eCTD application is to be submitted and the applicant wants to submit a test sequence)
- Determination of the deadlines to be respected by Swissmedic and by the applicant
- Planning of sample testing, where applicable.

However, the applicant can also briefly address particular problems at this Presubmission Meeting, e.g. special new manufacturing processes, specific statistical analyses, critical points, etc. that could affect the complexity of the evaluation. The definitive submission date (+5CD) is established at the Presubmission Meeting.

The following information / documentation must be sent to Swissmedic, with an appropriate cover letter, at the latest 2 weeks before the Presubmission Meeting:

- List of questions: Presentation of the issues to be clarified during the Presubmission Meeting, usually in the form of a Briefing Book (see section 3.2 List of questions/documentation in the guidance document *Meeting for applicants held with the Authorisation sector HMV4*),
- Draft agenda with the points to be discussed,
- Proposal for the type of meeting: in person, teleconference or videoconference and
- List of participants and their functions.

Furthermore, Presubmission Meetings in the PPN procedure are subject to the provisions of the guidance document *Company meetings in Authorisation HMV4*. The applicant is responsible for minuting the Presubmission Meeting. The applicant should send a copy of the minutes to Swissmedic 14 CD at the latest after the meeting. This meeting can also be waived by mutual agreement between Swissmedic and the applicant.

5.3 Authorisation procedure with PPN

5.3.1 Submission and documentation

The applicant submits the authorisation application to Swissmedic, including all documentation, on the agreed date (+5 CD) as an eCTD version or as a CTD paper version with CD/DVD (eDok).

The requirements governing the application documentation are the same as those applicable to an authorisation application outside the PPN process (see for example guidance documents *Authorisation of human medicinal product with known active pharmaceutical substance HMV4*, *Authorisation biosimilar HMV4*, *Variations and extensions HMV4* and the formal requirements as laid down in guidance document *Formal requirements HMV4* and the *Directory Overview of documents to be submitted HMV4*).

Any results from foreign assessments available to the applicant, and in particular assessment reports from the EMA or the FDA, must be included with the submission. If the date provided to the Agency for the submission (+5 CD) is not respected, or if the documentation submitted with the application has major shortcomings (which cannot be rectified by the applicant within 10 CD), with the result that the agreed schedule is unlikely to be observed, the submission will be accepted and processed as a normal authorisation application, i.e. outside the PPN procedure (subject to the normal flat fee specified in FeeO-Swissmedic and with no shortening of the processing period by 20%). The costs of examining the request and for the Presubmission Meeting will be billed on an hourly basis in accordance with Art. 4 para. 2 FeeO-Swissmedic.

5.3.2 Evaluation phase and periods

The evaluation takes place in accordance with the process for first authorisation of a New API / preparation specified in Art. 12 para. 5 TPLO, variations and authorisation extensions and the guidance document *Time limits for authorisation applications HMV4* and is subject to the shortened periods shown in the flow chart in section 7.

If a List of Questions (LoQ) is issued, the applicant informs Swissmedic within two weeks of the binding submission date for its reply to the LoQ. This information will enable Swissmedic to adapt its planning for evaluation phase II accordingly. The applicant must also inform Swissmedic, within two weeks of receipt of the preliminary decision, of the date by which it will send its reply (position statement and supporting documents) to the preliminary decision.

If the applicant submits a larger volume of documentation for assessment than is required to answer the questions (e.g. in reply to the LoQ or as a position statement on the preliminary decision), the Agency shall be granted the same number of calendar days as for the preceding application phase in order to evaluate this documentation (i.e. 100 CD for a comprehensive, unsolicited answer to the LoQ and 90 or 70 CD for a comprehensive unsolicited answer to the preliminary decision) and these days shall be at the expense of the applicant. Swissmedic also reserves the right to impose a surcharge determined by the time involved (Art. 5, para. 2, Fee-O Swissmedic).

5.3.3 Product information / labelling phase and packaging materials

The applicant should also submit an initial version of the product information and the draft packaging materials with its application.

After evaluation phase I, Swissmedic will send the applicant, together with the LoQ, packaging materials that have been corrected to reflect the status of the evaluation process, and a first corrected version of the Information for healthcare professionals. The corrections cover the following sections:

- Therapeutic indications/usage
- Dosage/administration
- Contraindications
- Warnings and precautions

The whole Information for healthcare professionals is sent to the applicant, together with a statement making it clear that only the aforementioned sections have been corrected. Swissmedic reserves the right to refrain from sending a revised Information for healthcare professionals and corrected packaging materials at this time if this does not seem appropriate on the grounds of major objections or other considerations. Furthermore, any of the aforementioned sections may be excluded from revision by Swissmedic at the time of the LoQ. Corrections to the sections may also be subject to modification in subsequent evaluation phases. If Swissmedic made corrections at the time of the LoQ, the applicant submits a second, modified version of the product information and modified packaging materials, if appropriate, together with its reply to the LoQ. In the event of a preliminary decision of approval, Swissmedic may, if necessary, require further corrections to the product information and packaging materials. The applicant must then submit correspondingly modified texts to Swissmedic together with its position statement on the preliminary decision. If, when it submits its reply to the preliminary decision, the applicant sends the Agency new suggestions or additional proposed corrections to the product information and/or the packaging materials, and if these require examination, the specified time limit for the labelling phase is extended accordingly. The processing time is then charged to the applicant. The approved texts are sent to the authorisation holder with the official decision letter and must then be published.

5.3.4 Sample testing

Sample testing by Swissmedic takes place in accordance with the requirements generally applicable to the authorisation procedure. The performance of sample testing and the timing and modalities for submitting the documentation and samples can be discussed and agreed upon in the Presubmission Meeting. Samples and any other documents must then be submitted in accordance with the requirements stated in the LoQ.

5.3.5 Failure to respect time limits

If Swissmedic is unable to observe the agreed processing periods / time limits, the Agency may not apply a surcharge for the authorisation procedure (time limits continue according to the PPN). However, if the applicant's failure to respect a time limit prevents adherence to the time schedule established for processing the application, the applicant will be charged the full surcharge, and the application will be treated as a normal authorisation application from the time at which the delay occurs, including the corresponding time limits and modalities. The applicant is also deemed to have

failed to observe the time limits if extensions to the time limits for replying to the LoQ, PD and text correction communication are granted (see flow chart in section 7).

5.3.6 Fees for applications in the PPN procedure

FeeO-Swissmedic applies, particularly Art. 7.


In the case of new authorisations of medicinal products with Orphan Drug Status (ODS), the supplement is payable but no flat fee is charged.

If there are justified reasons for halting or withdrawing the PPN procedure before processing of the application begins (i.e. specifically before the formal checks have been completed), a fee for the costs that have been incurred up to that point will be charged.

5.4 Flow chart

Before submission (request, examination, preparation for PPN)

After submission (PPN application)



Change history

Ver4.0sion	Change	sig
4.1	New layout, no content adjustments to the previous version.	dei
4.0	Restriction in Chapter 6.3.6 lifted: Fee reduction for collective applications according to Art. 11 FeeO-Swissmedic are possible	dts
3.2	Formal adjustments to the header and footer No content adjustments to the previous version.	dei
3.1	Clarification that extensions to the time limits for the company's reply to the letters (LoQ, PD and TC) sent to them by Swissmedic are also considered as failure to observe the time limits (section 6.3.5 Failure to respect time limits).	stb
3.0	Explanation regarding fees for applications in the PPN procedure (chapter 6.3.6): When applications for indication extensions are submitted for medicinal products in the same range under the procedure with prior notification (PPN), no fee reduction (joint discount) is granted.	stb
2.0	The procedure with prior notification (PPN) is now also possible for new authorisations of medicinal products with Orphan Drug Status (ODS – section 6.1 as amended). In such cases, the supplement is payable but no flat fee is charged.	stb
1.0	Implementation of TPO4	stb